Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

November 22, 2024

Study Completion Date

November 22, 2024

Conditions

Metastatic CancerSolid Tumor

Interventions

DRUG

Sym021

Sym021 is a humanized anti-PD-1 antibody.

DRUG

Sym024

Sym024 is an anti-CD73 antibody.

Trial Locations (4)

START Midwest, Grand Rapids

MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

Symphogen A/S

INDUSTRY

NCT04672434 - Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter